Login Register Cart 0
Infectious Disorders - Drug Targets

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Mucormycosis and COVID-19: Unraveling the Interplay of Fungal Infection in a Global Health Crisis: An Overview

Author(s): Ali Moheb-Alian, Ali Akbari, Saghi Nooraei, Howra Bahrulolum, Zoheir Mohammadian Farsani, Negin Mokhtari, Mozhdeh Sadat Ebadi, Arezoo Mohammadian Farsani, Seyedmoein Khatami, Mohammadmahdi Esmaeili, Zahra Keykhaee, Mohammad Hossein Heydargoy, Zahra Rafiei and Gholamreza Ahmadian*

Volume 25, Issue 4, 2025

Published on: 31 October, 2024

Article ID: e18715265310191

Pages: 21

DOI: 10.2174/0118715265310191240919060621

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

The healthcare system has been greatly affected by the COVID-19 pandemic, resulting in an increase in secondary and co-infections among patients. Factors like pulmonary damage and weakened immune systems make patients more susceptible to fungal infections. Mucormycosis, an opportunistic fungal infection, prospers in environments with limited oxygen, and elevated glucose levels due to conditions such as diabetes and steroid use, as well as in acidic environments from metabolic acidosis and diabetic ketoacidosis, where it demonstrates heightened germination ability. Recognizing these complications is critical to minimize harm to patients. The insights gained from this review can improve our understanding of how fungal infections develop in connection to COVID-19, leading to better predictive algorithms, tailored care plans, enhanced antifungal treatments, quicker diagnostics, and improved management strategies.

Keywords: COVID-19, mucormycosis, fungal infections, diabetes, immune suppression, acidic environment.

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Rahalkar MC, Bahulikar RA. Lethal pneumonia cases in Mojiang miners (2012) and the mineshaft could provide important clues to the origin of SARS-CoV-2. Front Public Health 2020; 8: 581569.
[http://dx.doi.org/10.3389/fpubh.2020.581569] [PMID: 33194988]
[2]
Gates B. Responding to Covid-19 — A Once-in-a-Century Pandemic? 2020.
[http://dx.doi.org/10.1056/NEJMp2003762?query=RP.]
[3]
Frutos R, Javelle E, Barberot C, Gavotte L, Tissot-Dupont H, Devaux CA. Origin of COVID-19: Dismissing the Mojiang mine theory and the laboratory accident narrative. Environ Res 2022; 204(Pt B): 112141.
[http://dx.doi.org/10.1016/j.envres.2021.112141] [PMID: 34597664]
[4]
Jones DS. History in a crisis - Lessons for COVID-19. N Engl J Med 2020; 382(18): 1681-3.
[http://dx.doi.org/10.1056/NEJMp2004361.]
[5]
Madabhavi I, Sarkar M, Kadakol N. COVID-19. A review. Monaldi Arch Chest Dis 2020; 90(2)
[http://dx.doi.org/10.4081/monaldi.2020.1298] [PMID: 32498503]
[6]
Ashique S. ‘Mucormycosis’: A Fungal Infection Threatening India During COVID-19′ - A Review. Antiinfect Agents 2022; 20(1): e301121198413.
[http://dx.doi.org/10.2174/2211352519666211130105217]
[7]
Garcia-Vidal C, Sanjuan G, Moreno-García E, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect 2021; 27(1): 83-8.
[http://dx.doi.org/10.1016/j.cmi.2020.07.041] [PMID: 32745596]
[8]
Khanna M, Challa S, Kabeil AS, et al. Risk of mucormycosis in diabetes mellitus: a systematic review. Cureus 2021; 13(10): e18827.
[http://dx.doi.org/10.7759/cureus.18827] [PMID: 34804684]
[9]
SeyedAlinaghi S, Karimi A, Barzegary A, et al. Mucormycosis infection in patients with COVID-19: A systematic review. Health Sci Rep 2022; 5(2): e529.
[http://dx.doi.org/10.1002/hsr2.529] [PMID: 35252593]
[10]
Prakash H, Skiada A, Paul RA, Chakrabarti A, Rudramurthy SM. Connecting the dots: interplay of pathogenic mechanisms between COVID-19 disease and mucormycosis. J Fungi (Basel) 2021; 7(8): 616.
[http://dx.doi.org/10.3390/jof7080616] [PMID: 34436155]
[11]
Prakash H, Chakrabarti A. Epidemiology of Mucormycosis in India. Microorganisms 2021; 9(3): 523.
[http://dx.doi.org/10.3390/microorganisms9030523] [PMID: 33806386]
[12]
Patel A, Agarwal R, Rudramurthy SM, et al. Multicenter epidemiologic study of coronavirus disease–associated mucormycosis, India. Emerg Infect Dis 2021; 27(9): 2349-59.
[http://dx.doi.org/10.3201/eid2709.210934] [PMID: 34087089]
[13]
John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel) 2021; 7(4): 298.
[http://dx.doi.org/10.3390/jof7040298] [PMID: 33920755]
[14]
Hoenigl M, Seidel D, Carvalho A, Rudramurthy SM, Arastehfar A, Gangneux JP, et al. The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries (preprint). Lancet Microbe 2021.
[15]
Patel A, Kaur H, Xess I, Michael J, Savio J, Rudramurthy S, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect 2020; 26(7): 944.e9-944.e15.
[http://dx.doi.org/10.1016/j.cmi.2019.11.021]
[16]
Prakash H, Ghosh AK, Rudramurthy SM, et al. A prospective multicenter study on mucormycosis in India: Epidemiology, diagnosis, and treatment. Med Mycol 2019; 57(4): 395-402.
[http://dx.doi.org/10.1093/mmy/myy060] [PMID: 30085158]
[17]
Calabretta E, Moraleda JM, Iacobelli M, et al. COVID‐19‐induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol 2021; 193(1): 43-51.
[http://dx.doi.org/10.1111/bjh.17240] [PMID: 33538335]
[18]
Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. Inflamm Res 2020; 69(12): 1181-9.
[http://dx.doi.org/10.1007/s00011-020-01401-6] [PMID: 32918567]
[19]
Huertas A, Montani D, Savale L, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? Eur Respir J 2020; 56(1): 2001634.
[http://dx.doi.org/10.1183/13993003.01634-2020] [PMID: 32554538]
[20]
Danion F, Letscher-Bru V, Guitard J, Sitbon K, Dellière S, Angoulvant A, et al. Coronavirus disease 2019-Associated mucormycosis in France: A rare but deadly complication. Open Forum Infect Dis 2021; 9(2): ofab566.
[http://dx.doi.org/10.1093/ofid/ofab566.]
[21]
Kumar M, Sarma DK, Shubham S, et al. Mucormycosis in COVID-19 pandemic: Risk factors and linkages. Curr Res Microb Sci 2021; 2: 100057.
[http://dx.doi.org/10.1016/j.crmicr.2021.100057] [PMID: 34396355]
[22]
Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15(4): 102146.
[http://dx.doi.org/10.1016/j.dsx.2021.05.019] [PMID: 34192610]
[23]
Hanley B, Naresh KN, Roufosse C, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe 2020; 1(6): e245-53.
[http://dx.doi.org/10.1016/S2666-5247(20)30115-4] [PMID: 32844161]
[24]
Monte Junior ES, Santos MEL, Ribeiro IB, et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. Clin Endosc 2020; 53(6): 746-9.
[http://dx.doi.org/10.5946/ce.2020.180] [PMID: 33207116]
[25]
Pasero D, Sanna S, Liperi C, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection 2021; 49(5): 1055-60.
[http://dx.doi.org/10.1007/s15010-020-01561-x] [PMID: 33331988]
[26]
Karimi‐Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). Int Forum Allergy Rhinol 2021; 11(6): 1029-30.
[http://dx.doi.org/10.1002/alr.22785.]
[27]
Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report. Eur J Ophthalmol 2022; 32(4): NP11-6.
[http://dx.doi.org/10.1177/11206721211009450] [PMID: 33843287]
[28]
Sargin F, Akbulut M, Karaduman S, Sungurtekin H. Severe rhinocerebral mucormycosis case developed after COVID 19. J Bacteriol Parasitol 2021; 12(1): 1000386.
[29]
Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. Cureus 2021; 13(2): e13163.
[http://dx.doi.org/10.7759/cureus.13163] [PMID: 33575155]
[30]
Zurl C, Hoenigl M, Schulz E, et al. Autopsy proven pulmonary mucormycosis due to Rhizopus microsporus in a critically ill COVID-19 patient with underlying hematological malignancy. J Fungi (Basel) 2021; 7(2): 88.
[http://dx.doi.org/10.3390/jof7020088] [PMID: 33513875]
[31]
Buil JB, van Zanten ARH, Bentvelsen RG, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, the Netherlands, December 2020 to May 2021. Euro Surveill 2021; 26(23): 2100510.
[http://dx.doi.org/10.2807/1560-7917.ES.2021.26.23.2100510] [PMID: 34114540]
[32]
Arana C, Cuevas Ramírez RE, Xipell M, et al. Mucormycosis associated with COVID‐19 in two kidney transplant patients. Transpl Infect Dis 2021; 23(4): e13652.
[http://dx.doi.org/10.1111/tid.13652] [PMID: 34038014]
[33]
Mulakavalupil B, Vaity C, Joshi S, Misra A, Pandit RA. Absence of Case of Mucormycosis (March 2020–May 2021) under strict protocol driven management care in a COVID-19 specific tertiary care intensive care unit. Diabetes Metab Syndr 2021; 15(4): 102169.
[http://dx.doi.org/10.1016/j.dsx.2021.06.006] [PMID: 34198110]
[34]
Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe 2022; 3(7): e543-52.
[http://dx.doi.org/10.1016/S2666-5247(21)00237-8] [PMID: 35098179]
[35]
Trieu TA, Navarro-Mendoza MI, Pérez-Arques C, et al. RNAi-based functional genomics identifies new virulence determinants in mucormycosis. PLoS Pathog 2017; 13(1): e1006150.
[http://dx.doi.org/10.1371/journal.ppat.1006150] [PMID: 28107502]
[36]
Zhou P, Li Z, Xie L, et al. Research progress and challenges to coronavirus vaccine development. J Med Virol 2021; 93(2): 741-54.
[http://dx.doi.org/10.1002/jmv.26517] [PMID: 32936465]
[37]
Varsha A. RNA viruses with central nervous system tropism. RNA Viruses and Neurological Disorders. CRC Press 2023; pp. 16-35.
[http://dx.doi.org/10.1201/9781003285823-3]
[38]
Laboratory testing of human suspected cases of novel coronavirus (nCoV) infection: Interim guidance, 10 January 2020. 2020. Available from: https://iris.who.int/handle/10665/330374
[39]
Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol 2020; 30(7): 1346-1351.e2.
[http://dx.doi.org/10.1016/j.cub.2020.03.063.]
[40]
Devaux CA, Fantini J. ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus. Front Microbiol 2023; 14: 1199561.
[http://dx.doi.org/10.3389/fmicb.2023.1199561] [PMID: 37520374]
[41]
Wadman M, Cohen J. Novavax vaccine delivers 89% efficacy against COVID-19 in UK—but is less potent in South Africa. Science 2021; 12: 2774.
[42]
Pouresmaieli M, Ekrami E, Akbari A, Noorbakhsh N, Moghadam NB, Mamoudifard M. A comprehensive review on efficient approaches for combating coronaviruses. Biomed Pharmacother 2021; 144: 112353.
[http://dx.doi.org/10.1016/j.biopha.2021.112353] [PMID: 34794240]
[43]
Yadav R, Chaudhary JK, Jain N, et al. Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19. Cells 2021; 10(4): 821.
[http://dx.doi.org/10.3390/cells10040821] [PMID: 33917481]
[44]
Calvaresi V, Wrobel AG, Toporowska J, et al. Structural dynamics in the evolution of SARS-CoV-2 spike glycoprotein. Nat Commun 2023; 14(1): 1421.
[http://dx.doi.org/10.1038/s41467-023-36745-0] [PMID: 36918534]
[45]
Chatterjee SK, Saha S, Munoz MNM. Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19. Front Mol Biosci 2020; 7: 196.
[http://dx.doi.org/10.3389/fmolb.2020.00196] [PMID: 32850977]
[46]
Jackson C, Farzan M, Chen B, Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat Rev Mol Cell Biol 2021; 10.
[PMID: 34611326]
[47]
Millet JK, Kien F, Cheung CY, et al. Ezrin interacts with the SARS coronavirus Spike protein and restrains infection at the entry stage. PLoS One 2012; 7(11): e49566.
[http://dx.doi.org/10.1371/journal.pone.0049566] [PMID: 23185364]
[48]
Song W, Gui M, Wang X, Xiang Y. Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathog 2018; 14(8): e1007236.
[http://dx.doi.org/10.1371/journal.ppat.1007236] [PMID: 30102747]
[49]
Tikellis C, Bernardi S, Burns WC. Angiotensin-converting enzyme 2 is a key modulator of the renin–angiotensin system in cardiovascular and renal disease. Curr Opin Nephrol Hypertens 2011; 20(1): 62-8.
[http://dx.doi.org/10.1097/MNH.0b013e328341164a] [PMID: 21099686]
[50]
Samavati L, Uhal BD. ACE DU. Much more than just a receptor for SARS-COV-2. Front Cell Infect Microbiol 2020; 10: 317.
[http://dx.doi.org/10.3389/fcimb.2020.00317] [PMID: 32582574]
[51]
Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock 2016; 46(3): 239-48.
[http://dx.doi.org/10.1097/SHK.0000000000000633] [PMID: 27082314]
[52]
Bourgonje AR, Abdulle AE, Timens W, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol 2020; 251(3): 228-48.
[http://dx.doi.org/10.1002/path.5471] [PMID: 32418199]
[53]
Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052.]
[54]
Böttcher-Friebertshäuser E, Freuer C, Sielaff F, et al. Cleavage of influenza virus hemagglutinin by airway proteases TMPRSS2 and HAT differs in subcellular localization and susceptibility to protease inhibitors. J Virol 2010; 84(11): 5605-14.
[http://dx.doi.org/10.1128/JVI.00140-10] [PMID: 20237084]
[55]
Belouzard S, Chu V, Whittaker G. Activación de la proteína de la espiga del coronavirus del SARS a través de la escisión proteolítica secuencial en dos sitios distintos. Proc Natl Acad Sci USA 2009; 106(14): 5871-6.
[http://dx.doi.org/10.1073/pnas.0809524106] [PMID: 19321428]
[56]
Wang H, Yang P, Liu K, et al. SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway. Cell Res 2008; 18(2): 290-301.
[http://dx.doi.org/10.1038/cr.2008.15] [PMID: 18227861]
[57]
Trus I, Udenze D, Berube N, et al. CpG-recoding in Zika virus genome causes host-age-dependent attenuation of infection with protection against lethal heterologous challenge in mice. Front Immunol 2020; 10: 3077.
[http://dx.doi.org/10.3389/fimmu.2019.03077] [PMID: 32038625]
[58]
Krishnakumar HN, Momtaz DA, Sherwani A, et al. Pathogenesis and progression of anosmia and dysgeusia during the COVID-19 pandemic. Eur Arch Otorhinolaryngol 2023; 280(2): 505-9.
[http://dx.doi.org/10.1007/s00405-022-07689-w] [PMID: 36209486]
[59]
Chegini Z, Didehdar M, Khoshbayan A, Rajaeih S, Salehi M, Shariati A. Epidemiology, clinical features, diagnosis and treatment of cerebral mucormycosis in diabetic patients: A systematic review of case reports and case series. Mycoses 2020; 63(12): 1264-82.
[http://dx.doi.org/10.1111/myc.13187] [PMID: 32965744]
[60]
Sharma B, Nonzom S. Mucormycosis and Its Upsurge During COVID-19 Epidemic: An Updated Review. Curr Microbiol 2023; 80(10): 322.
[http://dx.doi.org/10.1007/s00284-023-03430-w] [PMID: 37592083]
[61]
Riley TT, Muzny CA, Swiatlo E, Legendre DP. Breaking the Mold. Ann Pharmacother 2016; 50(9): 747-57.
[http://dx.doi.org/10.1177/1060028016655425] [PMID: 27307416]
[62]
Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect 2004; 10: 31-47.
[http://dx.doi.org/10.1111/j.1470-9465.2004.00843.x] [PMID: 14748801]
[63]
Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP. Pathogenesis of Mucormycosis. Clin Infect Dis 2012; 54(Suppl 1): S16-22.
[http://dx.doi.org/10.1093/cid/cir865] [PMID: 22247441]
[64]
Chander J. Textbook of Medical Mycology. 2017.
[65]
Mahalaxmi I, Jayaramayya K, Venkatesan D, et al. Mucormycosis: An opportunistic pathogen during COVID-19. Environ Res 2021; 201: 111643.
[http://dx.doi.org/10.1016/j.envres.2021.111643] [PMID: 34237335]
[66]
Hariprasath P, Arunaloke C. Epidemiologia Global da Mucormicose. J Fungi (Basel) 2019; 5(1): 26.
[http://dx.doi.org/10.3390/jof5010026] [PMID: 30901907]
[67]
Cinteza E, Nicolescu A, Ciomartan T, et al. Disseminated Cunninghamella spp. Endocarditis in a Beta-Thalassemia Patient after Asymptomatic COVID-19 Infection. Diagnostics (Basel) 2022; 12(3): 657.
[http://dx.doi.org/10.3390/diagnostics12030657] [PMID: 35328209]
[68]
Chakrabarti A, Kumar P, Padhye AA, et al. Primary cutaneous zygomycosis due to Saksenaea vasiformis and Apophysomyces elegans. Clin Infect Dis 1997; 24(4): 580-2.
[http://dx.doi.org/10.1093/clind/24.4.580] [PMID: 9145731]
[69]
Duan H, Chen X, Li Z, et al. Clofazimine improves clinical outcomes in multidrug-resistant tuberculosis: a randomized controlled trial. Clin Microbiol Infect 2019; 25(2): 190-5.
[http://dx.doi.org/10.1016/j.cmi.2018.07.012] [PMID: 30036672]
[70]
Phan QT, Myers CL, Fu Y, et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol 2007; 5(3): e64.
[http://dx.doi.org/10.1371/journal.pbio.0050064] [PMID: 17311474]
[71]
Das R, Roy J, Ashique S. Black Fungus: An Alarming Infection During Novel Coronavirus: A Review. Antiinfect Agents 2022; 20(4): e290322202776.
[http://dx.doi.org/10.2174/2211352520666220329160041]
[72]
Ashique S, Gupta K, Gupta G, et al. Vitamin D-A prominent immunomodulator to prevent COVID-19 infection. Int J Rheum Dis 2023; 26(1): 13-30.
[http://dx.doi.org/10.1111/1756-185X.14477] [PMID: 36308699]
[73]
Ashique S, Chaudhary V, Pal S, et al. Marburg virus-a threat during SARS-CoV-2 era: a review. Infect Disord Drug Targets 2023; 23(5): e280223214111.
[http://dx.doi.org/10.2174/1871526523666230228103845] [PMID: 36852815]
[74]
Schulz A, Dürr C, Zenz T, et al. Lenalidomide reduces survival of chronic lymphocytic leukemia cells in primary cocultures by altering the myeloid microenvironment. Blood 2013; 121(13): 2503-11.
[http://dx.doi.org/10.1182/blood-2012-08-447664] [PMID: 23349394]
[75]
Azhar A, Khan WH, Khan PA, Alhosaini K, Owais M, Ahmad A. Mucormycosis and COVID-19 pandemic: Clinical and diagnostic approach. J Infect Public Health 2022; 15(4): 466-79.
[http://dx.doi.org/10.1016/j.jiph.2022.02.007] [PMID: 35216920]
[76]
Hoffmann K, Pawłowska J, Walther G, et al. The family structure of the Mucorales a synoptic revision based on comprehensive multigene-genealogies. Persoonia 2013; 30(1): 57-76.
[http://dx.doi.org/10.3767/003158513X666259] [PMID: 24027347]
[77]
Lecointe K, Cornu M, Leroy J, Coulon P, Sendid B. Polysaccharides cell wall architecture of Mucorales. Front Microbiol 2019; 10: 469.
[http://dx.doi.org/10.3389/fmicb.2019.00469] [PMID: 30941108]
[78]
Angebault C, Lanternier F, Dalle F, Schrimpf C, Roupie A-L, Dupuis A, et al. Prospective evaluation of serum β-glucan testing in patients with probable or proven fungal diseases. Open Forum Infect Dis 2016; 3(3): ofw128.
[http://dx.doi.org/10.1093/ofid/ofw128.]
[79]
Yamazaki H, Shiraishi N, Takeuchi K, Ohnishi Y, Horinouchi S. Characterization of alg2 encoding a mannosyltransferase in the zygomycete fungus Rhizomucor pusillus. Gene 1998; 221(2): 179-84.
[http://dx.doi.org/10.1016/S0378-1119(98)00456-9] [PMID: 9795208]
[80]
Ghuman H, Voelz K. Innate and adaptive immunity to mucorales. J Fungi (Basel) 2017; 3(3)
[http://dx.doi.org/10.3390/jof3030048.]
[81]
Morin-Sardin S, Nodet P, Coton E, Jany JL. Mucor: A Janus-faced fungal genus with human health impact and industrial applications. Fungal Biol Rev 2017; 31(1): 12-32.
[http://dx.doi.org/10.1016/j.fbr.2016.11.002]
[82]
Liu D. Classification of medically important fungi. In: Molecular Medical Microbiology. Elsevier 2024; pp. 2763-77.
[http://dx.doi.org/10.1016/B978-0-12-818619-0.00034-4.]
[83]
Ibrahim A, Edwards J, Filler S. Zygomycoses. In: Dismukes WE, Pappas PG, Sobel JD, Eds. Clinical Mycology. 2003.
[http://dx.doi.org/10.1093/oso/9780195148091.003.0015.]
[84]
Baldin C, Ibrahim AS. Molecular mechanisms of mucormycosis—The bitter and the sweet. PLoS Pathog 2017; 13(8): e1006408.
[http://dx.doi.org/10.1371/journal.ppat.1006408] [PMID: 28771587]
[85]
Sharma A, Alam MA, Dhoundiyal S, Sharma PK. Review on Mucormycosis: Pathogenesis, Epidemiology, Microbiology and Diagnosis. Infect Disord Drug Targets 2024; 24(1): e220823220209.
[http://dx.doi.org/10.2174/1871526523666230822154407] [PMID: 37608614]
[86]
Timpl R, Rohde H, Robey PG, Rennard SI, Foidart JM, Martin GR. Laminin–a glycoprotein from basement membranes. J Biol Chem 1979; 254(19): 9933-7.
[http://dx.doi.org/10.1016/S0021-9258(19)83607-4] [PMID: 114518]
[87]
Bouchara JP, Oumeziane NA, Lissitzky JC, Larcher G, Tronchin G, Chabasse D. Attachment of spores of the human pathogenic fungus Rhizopus oryzae to extracellular matrix components. Eur J Cell Biol 1996; 70(1): 76-83.
[PMID: 8738422]
[88]
Ibrahim AS, Spellberg B, Avanessian V, Fu Y, Edwards JE Jr. Rhizopus oryzae adheres to, is phagocytosed by, and damages endothelial cells in vitro. Infect Immun 2005; 73(2): 778-83.
[http://dx.doi.org/10.1128/IAI.73.2.778-783.2005] [PMID: 15664916]
[89]
Liu M, Spellberg B, Phan QT, et al. The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice. J Clin Invest 2010; 120(6): 1914-24.
[http://dx.doi.org/10.1172/JCI42164] [PMID: 20484814]
[90]
Liu H, Lee MJ, Solis NV, et al. Aspergillus fumigatus CalA binds to integrin α5β1 and mediates host cell invasion. Nat Microbiol 2016; 2(2): 16211.
[http://dx.doi.org/10.1038/nmicrobiol.2016.211] [PMID: 27841851]
[91]
Upadhyay SK, Mahajan L, Ramjee S, Singh Y, Basir SF, Madan T. Identification and characterization of a laminin-binding protein of Aspergillus fumigatus: extracellular thaumatin domain protein (AfCalAp). J Med Microbiol 2009; 58(6): 714-22.
[http://dx.doi.org/10.1099/jmm.0.005991-0] [PMID: 19429746]
[92]
Bouvet M, Debarnot C, Imbert I, et al. In vitro reconstitution of SARS-coronavirus mRNA cap methylation. PLoS Pathog 2010; 6(4): e1000863.
[http://dx.doi.org/10.1371/journal.ppat.1000863] [PMID: 20421945]
[93]
Gebremariam T, Alkhazraji S, Soliman SSM, et al. Anti-CotH3 antibodies protect mice from mucormycosis by prevention of invasion and augmenting opsonophagocytosis. Sci Adv 2019; 5(6): eaaw1327.
[http://dx.doi.org/10.1126/sciadv.aaw1327] [PMID: 31206021]
[94]
Chibucos MC, Soliman S, Gebremariam T, et al. An integrated genomic and transcriptomic survey of mucormycosis-causing fungi. Nat Commun 2016; 7(1): 12218.
[http://dx.doi.org/10.1038/ncomms12218] [PMID: 27447865]
[95]
Gebremariam T, Liu M, Luo G, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest 2014; 124(1): 237-50.
[http://dx.doi.org/10.1172/JCI71349] [PMID: 24355926]
[96]
Wächtler B, Citiulo F, Jablonowski N, et al. Candida albicans-epithelial interactions: dissecting the roles of active penetration, induced endocytosis and host factors on the infection process. PLoS One 2012; 7(5): e36952.
[http://dx.doi.org/10.1371/journal.pone.0036952] [PMID: 22606314]
[97]
Tahiri G, Lax C, Cánovas-Márquez JT, et al. Mucorales and mucormycosis: Recent insights and future prospects. J Fungi (Basel) 2023; 9(3): 335.
[http://dx.doi.org/10.3390/jof9030335] [PMID: 36983503]
[98]
Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54: S23-34.
[http://dx.doi.org/10.1093/cid/cir866] [PMID: 22247442]
[99]
Thomas RJ. Particle size and pathogenicity in the respiratory tract. Virulence 2013; 4(8): 847-58.
[http://dx.doi.org/10.4161/viru.27172] [PMID: 24225380]
[100]
Honavar SG, Sen M, Lahane S, Lahane TP, Parekh R. Mucor in a viral land: a tale of two pathogens. Indian J Ophthalmol 2021; 69(2): 244-52.
[http://dx.doi.org/10.4103/ijo.IJO_3774_20] [PMID: 33463566]
[101]
Chamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrob Agents Chemother 2008; 52(2): 722-4.
[http://dx.doi.org/10.1128/AAC.01136-07] [PMID: 18025115]
[102]
Ma LJ, Ibrahim AS, Skory C, et al. Genomic analysis of the basal lineage fungus Rhizopus oryzae reveals a whole-genome duplication. PLoS Genet 2009; 5(7): e1000549.
[http://dx.doi.org/10.1371/journal.pgen.1000549] [PMID: 19578406]
[103]
Howard DH. Acquisition, transport, and storage of iron by pathogenic fungi. Clin Microbiol Rev 1999; 12(3): 394-404.
[http://dx.doi.org/10.1128/CMR.12.3.394] [PMID: 10398672]
[104]
Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982; 31(12): 1109-14.
[http://dx.doi.org/10.2337/diacare.31.12.1109] [PMID: 6816646]
[105]
Liu M, Lin L, Gebremariam T, et al. Fob1 and Fob2 proteins are virulence determinants of Rhizopus oryzae via facilitating iron uptake from ferrioxamine. PLoS Pathog 2015; 11(5): e1004842.
[http://dx.doi.org/10.1371/journal.ppat.1004842] [PMID: 25974051]
[106]
Brunke S, Mogavero S, Kasper L, Hube B. Virulence factors in fungal pathogens of man. Curr Opin Microbiol 2016; 32: 89-95.
[http://dx.doi.org/10.1016/j.mib.2016.05.010] [PMID: 27257746]
[107]
Pourazizi M, Hakamifard A, Peyman A, et al. COVID‐19 associated mucormycosis surge: A review on multi‐pathway mechanisms. Parasite Immunol 2024; 46(1): e13016.
[http://dx.doi.org/10.1111/pim.13016] [PMID: 37846902]
[108]
Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis 2012; 54: S61-6.
[http://dx.doi.org/10.1093/cid/cir869] [PMID: 22247447]
[109]
Castillo P, Wright KE, Kontoyiannis DP, et al. A new method for reactivating and expanding T cells specific for Rhizopus oryzae. Mol Ther Methods Clin Dev 2018; 9: 305-12.
[http://dx.doi.org/10.1016/j.omtm.2018.03.003] [PMID: 30038934]
[110]
Potenza L, Vallerini D, Barozzi P, et al. Mucorales-specific T cells emerge in the course of invasive mucormycosis and may be used as a surrogate diagnostic marker in high-risk patients. Blood 2011; 118(20): 5416-9.
[http://dx.doi.org/10.1182/blood-2011-07-366526] [PMID: 21931119]
[111]
Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. Cell Death Differ 2020; 27(5): 1451-4.
[http://dx.doi.org/10.1038/s41418-020-0530-3] [PMID: 32205856]
[112]
Lambert N, El-Azab SA, Ramrakhiani NS, et al. The other COVID-19 survivors: Timing, duration, and health impact of post-acute sequelae of SARS-CoV-2 infection. J Clin Nurs 2024; 33(1): 76-88.
[http://dx.doi.org/10.1111/jocn.16541] [PMID: 36181315]
[113]
Popko K, Gorska E, Stelmaszczyk-Emmel A, et al. Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects. Eur J Med Res 2010; 15(S2): 120-2.
[http://dx.doi.org/10.1186/2047-783X-15-S2-120] [PMID: 21147638]
[114]
Pinto LMO, Oliveira SA, Braga ELA, Nogueira RMR, Kubelka CF. Increased pro-inflammatory cytokines (TNF-alpha and IL-6) and anti-inflammatory compounds (sTNFRp55 and sTNFRp75) in Brazilian patients during exanthematic dengue fever. Mem Inst Oswaldo Cruz 1999; 94(3): 387-94.
[http://dx.doi.org/10.1590/S0074-02761999000300019] [PMID: 10348988]
[115]
Hasan SS, Capstick T, Ahmed R, et al. Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Rev Respir Med 2020; 14(11): 1149-63.
[http://dx.doi.org/10.1080/17476348.2020.1804365] [PMID: 32734777]
[116]
Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodríguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev 2020; 54: 62-75.
[http://dx.doi.org/10.1016/j.cytogfr.2020.06.001] [PMID: 32513566]
[117]
Angelico R, Blasi F, Manzia TM, Toti L, Tisone G, Cacciola R. The management of immunosuppression in kidney transplant recipients with COVID-19 disease: an update and systematic review of the literature. Medicina (Kaunas) 2021; 57(5): 435.
[http://dx.doi.org/10.3390/medicina57050435] [PMID: 33946462]
[118]
Bhanuprasad K, Manesh A, Devasagayam E, et al. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int J Infect Dis 2021; 111: 267-70.
[http://dx.doi.org/10.1016/j.ijid.2021.08.037] [PMID: 34450284]
[119]
Wong LYR, Perlman S. Immune dysregulation and immunopathology induced by SARS-CoV-2 and related coronaviruses — are we our own worst enemy? Nat Rev Immunol 2022; 22(1): 47-56.
[http://dx.doi.org/10.1038/s41577-021-00656-2] [PMID: 34837062]
[120]
Tahaghoghi-Hajghorbani S, Zafari P, Masoumi E, et al. The role of dysregulated immune responses in COVID-19 pathogenesis. Virus Res 2020; 290: 198197.
[http://dx.doi.org/10.1016/j.virusres.2020.198197] [PMID: 33069815]
[121]
Mihai FC. Assessment of COVID-19 waste flows during the emergency state in Romania and related public health and environmental concerns. Int J Environ Res Public Health 2020; 17(15): 5439.
[http://dx.doi.org/10.3390/ijerph17155439] [PMID: 32731593]
[122]
Ashique S, Mishra N, Garg A, et al. A Critical Review on the Long-Term COVID-19 Impacts on Patients With Diabetes. Am J Med 2024; S0002-9343(24)00133-5.
[http://dx.doi.org/10.1016/j.amjmed.2024.02.029] [PMID: 38485111]
[123]
Faiyazuddin M, Sophia A, Ashique S, et al. Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review. Front Immunol 2023; 14: 1264502.
[http://dx.doi.org/10.3389/fimmu.2023.1264502] [PMID: 37818370]
[124]
Li Q, Wang Y, Sun Q, et al. Immune response in COVID-19: what is next? Cell Death Differ 2022; 29(6): 1107-22.
[http://dx.doi.org/10.1038/s41418-022-01015-x] [PMID: 35581387]
[125]
Feldman C, Anderson R. The role of co-infections and secondary infections in patients with COVID-19. Pneumonia 2021; 13(1): 5.
[http://dx.doi.org/10.1186/s41479-021-00083-w] [PMID: 33894790]
[126]
Lin E, Moua T, Limper AH. Pulmonary mucormycosis: clinical features and outcomes. Infection 2017; 45(4): 443-8.
[http://dx.doi.org/10.1007/s15010-017-0991-6] [PMID: 28220379]
[127]
White PL, Dhillon R, Cordey A, et al. A national strategy to diagnose coronavirus disease 2019–associated invasive fungal disease in the intensive care unit. Clin Infect Dis 2021; 73(7): e1634-44.
[http://dx.doi.org/10.1093/cid/ciaa1298] [PMID: 32860682]
[128]
Kothandaraman N, Rengaraj A, Xue B, et al. COVID-19 endocrinopathy with hindsight from SARS. Am J Physiol Endocrinol Metab 2021; 320(1): E139-50.
[http://dx.doi.org/10.1152/ajpendo.00480.2020] [PMID: 33236920]
[129]
Rudrapal M, Khairnar SJ, Borse LB, Jadhav AG. Coronavirus disease-2019 (COVID-19): an updated review. Drug Res (Stuttg) 2020; 70(9): 389-400.
[http://dx.doi.org/10.1055/a-1217-2397] [PMID: 32746481]
[130]
Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect 2019; 25(1): 26-34.
[http://dx.doi.org/10.1016/j.cmi.2018.07.011] [PMID: 30036666]
[131]
Raw RK, Kelly CA, Rees J, Wroe C, Chadwick DR. Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination. J Infect 2021; 83(3): 381-412.
[http://dx.doi.org/10.1016/j.jinf.2021.05.035] [PMID: 34062184]
[132]
Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: A case report. Int J Surg Case Rep 2021; 82: 105957.
[http://dx.doi.org/10.1016/j.ijscr.2021.105957] [PMID: 33964720]
[133]
Yasmin F, Najeeb H, Naeem A, et al. COVID-19 associated mucormycosis: A systematic review from diagnostic challenges to management. Diseases 2021; 9(4): 65.
[http://dx.doi.org/10.3390/diseases9040065] [PMID: 34698143]
[134]
Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient – Case report and review of literature. J Mycol Med 2021; 31(2): 101125.
[http://dx.doi.org/10.1016/j.mycmed.2021.101125] [PMID: 33857916]
[135]
Fu Y, Yang Q, Xu M, Kong H, Chen H, Fu Y, et al. Secondary bacterial infections in critical ill patients with coronavirus disease 2019. Open Forum Infect Dis 2020; 7(6): ofaa220.
[http://dx.doi.org/10.1093/ofid/ofaa220.]
[136]
Tabassum T, Araf Y, Moin AT, Rahaman TI, Hosen MJ. COVID-19-associated-mucormycosis: possible role of free iron uptake and immunosuppression. Mol Biol Rep 2021; 1-8.
[PMID: 34709573]
[137]
Huang C, Huang L, Wang Y, et al. RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397(10270): 220-32.
[http://dx.doi.org/10.1016/S0140-6736(20)32656-8] [PMID: 33428867]
[138]
Noreen S, Maqbool I, Madni A. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic. Eur J Pharmacol 2021; 894: 173854.
[http://dx.doi.org/10.1016/j.ejphar.2021.173854] [PMID: 33428898]
[139]
Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. Med Mycol Case Rep 2021; 32: 64-7.
[http://dx.doi.org/10.1016/j.mmcr.2021.03.006] [PMID: 33842203]
[140]
Mohiuddin A, Mondal S. Advancement of Computational Design Drug Delivery System in COVID-19: Current Updates and Future Crosstalk- A Critical update. Infect Disord Drug Targets 2023; 23(8): 73-88.
[PMID: 37584349]
[141]
Abdoli A, Falahi S, Kenarkoohi A. COVID-19-associated opportunistic infections: a snapshot on the current reports. Clin Exp Med 2021; 22(3): 327-46.
[http://dx.doi.org/10.1007/s10238-021-00751-7] [PMID: 34424451]
[142]
Rodriguez-Morales AJ, Mamani-García CS, Nuñez-Lupaca JN, et al. COVID-19 and mucormycosis in Latin America – An emerging concern. Travel Med Infect Dis 2021; 44: 102156.
[http://dx.doi.org/10.1016/j.tmaid.2021.102156] [PMID: 34454089]
[143]
Al-Tawfiq JA, Alhumaid S, Alshukairi AN, et al. COVID-19 and mucormycosis superinfection: the perfect storm. Infection 2021; 49(5): 833-53.
[http://dx.doi.org/10.1007/s15010-021-01670-1] [PMID: 34302291]
[144]
Montaño DE, Voigt K. Host immune defense upon fungal infections with mucorales: pathogen-immune cell interactions as drivers of inflammatory responses. J Fungi (Basel) 2020; 6(3): 173.
[http://dx.doi.org/10.3390/jof6030173] [PMID: 32957440]
[145]
Wang M, Wey S, Zhang Y, Ye R, Lee AS. Role of the unfolded protein response regulator GRP78/BiP in development, cancer, and neurological disorders. Antioxid Redox Signal 2009; 11(9): 2307-16.
[http://dx.doi.org/10.1089/ars.2009.2485] [PMID: 19309259]
[146]
Chinn RY, Diamond RD. Generation of chemotactic factors by Rhizopus oryzae in the presence and absence of serum: relationship to hyphal damage mediated by human neutrophils and effects of hyperglycemia and ketoacidosis. Infect Immun 1982; 38(3): 1123-9.
[http://dx.doi.org/10.1128/iai.38.3.1123-1129.1982] [PMID: 6818145]
[147]
Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984; 74(1): 150-60.
[http://dx.doi.org/10.1172/JCI111395] [PMID: 6736246]
[148]
Lamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of Zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 2009; 199(9): 1399-406.
[http://dx.doi.org/10.1086/597615] [PMID: 19358672]
[149]
Goudarzi M, Rashidi M, Rezaei M. Study of Nonenzymatic Glycation of Transferrin and its Effect on Iron–Binding Antioxidant Capacity. Iran J Basic Med Sci 2010.
[150]
Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004; 27(10): 2422-8.
[http://dx.doi.org/10.2337/diacare.27.10.2422] [PMID: 15451911]
[151]
Ashourpour M, Djalali M, Djazayery A, Eshraghian MR, Taghdir M, Saedisomeolia A. Relationship between serum ferritin and inflammatory biomarkers with insulin resistance in a Persian population with type 2 diabetes and healthy people. Int J Food Sci Nutr 2010; 61(3): 316-23.
[http://dx.doi.org/10.3109/09637480903555150] [PMID: 20113186]
[152]
Rahman FI, Islam MR, Bhuiyan MA. Mucormycosis or black fungus infection is a new scare in South Asian countries during the COVID‐19 pandemic: Associated risk factors and preventive measures. J Med Virol 2021; 93(12): 6447-8.
[http://dx.doi.org/10.1002/jmv.27207] [PMID: 34260073]
[153]
Pakdel F, Ahmadikia K, Salehi M, et al. Mucormycosis in patients with COVID‐19: A cross‐sectional descriptive multicentre study from Iran. Mycoses 2021; 64(10): 1238-52.
[http://dx.doi.org/10.1111/myc.13334] [PMID: 34096653]
[154]
Monika P, Chandraprabha MN. Risks of mucormycosis in the current COVID-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients. Mol Biol Rep 2022; 49(6): 4977-88.
[http://dx.doi.org/10.1007/s11033-022-07160-3] [PMID: 35107737]
[155]
Imran M, A S A, Tauseef M, Khan SA, Hudu SA, Abida . Mucormycosis medications: a patent review. Expert Opin Ther Pat 2021; 31(11): 1059-74.
[http://dx.doi.org/10.1080/13543776.2021.1939308] [PMID: 34082658]
[156]
Haque H, Nettboy S, Kumar S. Surgical-site mucormycosis infection in a solid-organ transplant recipient and a concise review of the literature. BMJ Case Rep 2019; 12(12): e229687.
[http://dx.doi.org/10.1136/bcr-2019-229687] [PMID: 31826901]
[157]
Horger M, Hebart H, Schimmel H, et al. Disseminated mucormycosis in haematological patients: CT and MRI findings with pathological correlation. Br J Radiol 2006; 79(945): e88-95.
[http://dx.doi.org/10.1259/bjr/16038097] [PMID: 16940368]
[158]
Rocha ICN, Hasan MM, Goyal S, et al. COVID‐19 and mucormycosis syndemic: double health threat to a collapsing healthcare system in India. Trop Med Int Health 2021; 26(9): 1016-8.
[http://dx.doi.org/10.1111/tmi.13641] [PMID: 34117677]
[159]
Honavar S. Code mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021; 69(6): 1361-5.
[http://dx.doi.org/10.4103/ijo.IJO_1165_21] [PMID: 34011699]
[160]
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19(12): e405-21.
[http://dx.doi.org/10.1016/S1473-3099(19)30312-3] [PMID: 31699664]
[161]
Mekki SO, Hassan AA, Falemban A, Alkotani N, Alsharif SM, Haron A, et al. Pulmonary Mucormycosis: A Case report of a rare infection with potential diagnostic problems. Case Rep Pathol 2020; 2020: 5845394.
[http://dx.doi.org/10.1155/2020/5845394]
[162]
Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, et al. Diagnosis and treatment of mucormycosis in patients with hematological malignancies: Guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2013; 98(4): 492-504.
[http://dx.doi.org/10.3324/haematol.2012.065110.]
[163]
Barh D, Aljabali AA, Tambuwala MM, et al. Predicting COVID-19—comorbidity pathway crosstalk-based targets and drugs: towards personalized COVID-19 management. Biomedicines 2021; 9(5): 556.
[http://dx.doi.org/10.3390/biomedicines9050556] [PMID: 34067609]
[164]
Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? Med Sci Monit 2004; 10(5): RA111-23.
[PMID: 15114285]
[165]
Sarfraz Z, Sarfraz A, Jaiswal V, et al. The Past, Present and Future of COVID-19 Associated Mucormycosis: A Rapid Review. J Prim Care Community Health 2022; 13
[http://dx.doi.org/10.1177/21501319221099476] [PMID: 35587142]
[166]
Garre V. Recent Advances and Future Directions in the Understanding of Mucormycosis. Front Cell Infect Microbiol 2022; 12: 850581.
[http://dx.doi.org/10.3389/fcimb.2022.850581] [PMID: 35281441]
[167]
G Alshahawey M, S El-Housseiny G, S Elsayed N, Y Alshahrani M, Wakeel LMEL, M Aboshanab K. New insights on mucormycosis and its association with the COVID-19 pandemic. Future Sci OA 2022; 8(2): FSO772.
[http://dx.doi.org/10.2144/fsoa-2021-0122] [PMID: 35059222]
[168]
Lamoth F, Lewis RE, Kontoyiannis DP. Investigational antifungal agents for invasive mycoses: a clinical perspective. Clin Infect Dis 2022; 75(3): 534-44.
[http://dx.doi.org/10.1093/cid/ciab1070] [PMID: 34986246]
[169]
Syed-Abdul S, Babu AS, Bellamkonda RS, Itumalla R, Acharyulu G, Krishnamurthy S, et al. Using artificial intelligence-based models to predict the risk of mucormycosis among COVID-19 survivors: An experience from India. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.09.13.21263511]
[170]
Acosta-España JD, Voigt K. Mini review: Risk assessment, clinical manifestation, prediction, and prognosis of mucormycosis: Implications for pathogen- and human-derived biomarkers. Front Microbiol 2022; 13: 895989.
[http://dx.doi.org/10.3389/fmicb.2022.895989.]
[171]
Dopazo J, Maya-Miles D, García F, et al. Implementing personalized medicine in COVID-19 in andalusia: An opportunity to transform the healthcare system. J Pers Med 2021; 11(6): 475.
[http://dx.doi.org/10.3390/jpm11060475] [PMID: 34073493]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 34
Html icon 1
Find your institution